利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究被引量：47

Effects of liraglutide on hepatic fat deposition in obese patients with type 2 diabets and non-alcoholic fatty liver disease

下载PDF

导出

摘要目的探讨利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响。方法 71例经二甲双胍单药治疗血糖控制不佳的肥胖2型糖尿病合并非酒精性脂肪肝患者使用利拉鲁肽治疗6个月,观察治疗后血糖、血脂、血压相关指标的变化,采用瞬时弹性成像技术评价肝脏脂肪沉积情况。结果加用利拉鲁肽治疗后患者的空腹血糖(FPG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)、体质量指数(BMI)和胰岛素抵抗指数(HOMA-IR)较治疗前降低(P<0.01);脂肪受控衰减参数及肝脏硬度也明显降低(P<0.01)。结论利拉鲁肽治疗肥胖2型糖尿病合并非酒精性脂肪肝患者能降低血糖、血脂和血压水平,还可以改善患者的肝脏脂肪沉积。 Objective To investigate the efftects of liraglutide on hepatic fat deposition in obese patients with type 2 diabets and non-alcoholic fatty liver disease. Methods Totally 71 obese＇patients with type 2 diabetes and non-alcoholic fatty liver disease which have poor glycemic control undergoing single antidiabetic-drug treatment with metformin were participated in the study. The patients were treated with liraglutide for 6 month. FBG, 2hPBG, HbA1C, BMI, HOMA-IR, CAP and LSM were measured, transient elastic imaging technique was used to Evaluate the hepatic fat deposition. Results After liraglutide therapy,FBG,2hPBG, HbA1C, BMI,HOMA-IR were significantly decreased （P〈0.01） ;CAP and LSM were also decreased （P〈0.01）. Conclusion Treatment with liraglutide on top of ongoing rnetformin therapy in obese patients with type 2 diabetes and non-alcoholic fatty liver significantly reduces the hepatic fat deposition.

作者杨帆李钶蒋晓岚李健王翔曾庆华余婷婷

机构地区四川省医学科学院/四川省人民医院全科医学中心四川大学华西医院金卡医院重庆医科大学附属第二医院内分泌科四川大学华西保健医院内分泌及代谢科

出处《重庆医学》 CAS 北大核心 2016年第25期3493-3495,共3页 Chongqing medicine

基金四川省卫生厅科研基金项目(120116)

关键词糖尿病 2型利拉鲁肽非酒精性脂肪肝肥胖肝脏脂肪沉积 diabetes mellitus,type 2 liraglutide non-alcoholic fatty liver disease obesity hepatic fat deposition

分类号 R587.1 [医药卫生—内分泌] R589.2 [医药卫生—内分泌] R575.5 [医药卫生—消化系统]

引文网络
相关文献

参考文献20

1Vernon G,Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults [J].Alim Pharmacol Thers,2011,30(3) :274-285.
2Praveenraj P, Gomes RM, Kumar S,et al. Prevalence and predictors of non -alcoholic fatty liver disease in morbidly obese south Indian patients undergoing bariatric surgery [J]. Obes Surg,2015,25(11) :2078-2087.
3Conlon BA, Beasley JM, Aebersold K, et al. Nutritional management of insulin resistance in nonalcoholic fatty liv- er disease (NAFLD) [J]. Nutrients, 2013,5 (10) : 4093- 4114.
4Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians[J]. J Family ivied Prim Care,2015,4(1) :45-52.
5Lonardo A,Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome [J]. Dig Liver Dis,2015,47(3) :181-190.
6牛颜丽,吴国富,袁靖.胰岛素治疗的肥胖2型糖尿病患者加用利拉鲁肽的临床疗效研究[J].中国全科医学,2014,17(1):56-60. 被引量：61
7Kumar M, Rastogi A, Singh T, et al. Controlled attenua- tion parameter for non-invasive assessment of hepatic steatosis : does etiology affect performance[J]. J Gastroen- terol Hepatol, 2013,28(7) : 1194-1201.
8Douali N, Abdennour M, Sasso M, et al. Noninvasive diag- nosis of nonalcoholic steatohepatitis disease based on clin- ical decision support system[J]. Stud Health Technol In- form, 2013,192 : 1178.
9Myers RP,Pomier-Layrargues G,Kirsch R,et al. Feasibil- ity and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients[J]. H epatology, 2012,55 (1) : 199-208.
10Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome [J]. Dig Liver Dis,2015,47(3):181-190.

二级参考文献21

1李霞,周智广,亓海英,陈小燕,黄干.用空腹C肽代替胰岛素改良Homa公式评价胰岛素抵抗和胰岛β细胞功能[J].中南大学学报（医学版）,2004,29(4):419-423. 被引量：212
2马晓霞,杨翠珍,牟景敏.杏丁注射液联合二甲双胍治疗2型糖尿病[J].中闰实验方剂学杂志,2011,17(4):205-207.
3Ning G, Hong J, Bi Y, et al. Progress in diabetes research in China [J]. JDiabetes, 2009, 1 (3): 163-172.
4World Health Organizationl. Definition, diagnosis and classification of diabetes mellitus and its complications [ Z] . WHO/NCD/NCS, 1999.
5Horowitz M, Flint A, Jones KL, et al. Effect of the once - daily human GLP- 1 analogue liraglutide on appetite, energy intake, energy ex- penditure and gastric emptying in type 2 diabetes [ J ]. Diabetes Res Clin Praet, 2012, 97 (2): 258-266.
6Marre M, Shaw J, Braindle M, et al. Liraglutide, a once - daily human GLP - 1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glyeaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes ( LEAD - I SU) . Diabet Med, 2009, 26 (3): 268-278.
7Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once - daily human GLP - 1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes [ J ]. Curr Med Res Opin, 2010, 26 (5): 1013-1022.
8Suzuki D, Toyoda M, Kimura M, et al. Effects of liraglutide, a human glucagon - like peptide - 1 analogue, on body weight, body fat area and body fat- related markers in patients with type 2 diabetes mellitus [ J]. InternMed, 2013, 52 (10): 1029-1034.
9Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is asso- ciated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) trials [J]. J Clin Endocrinol Metab, 2011, 96 (6) : 1695 - 1702.
10Marl A, Degn K, Brock B, et al. Effects of the long - acting human glucagon -like peptide - 1 analog liraglutide on beta - cell function in normal living conditions [ J]. Diabetes Care, 2007, 30 (8) : 2032 - 2033.